Key Investor Signals
70% patient follow-up rate signals early retention
Mothercore reports that 70% of patients book a follow-up consultation after their initial virtual pelvic-floor physiotherapy session.
Fertifa partnership adds an employer-funded route to care
Mothercore sessions are reimbursable for employees whose workplace offers Fertifa, adding an employer-benefits payment channel alongside direct self-pay.
5 partner contracts expand Mothercore beyond direct-to-consumer sales
Mothercore has signed five partner contracts, creating additional routes to reach patients through healthcare and employee-benefit partners.
Other Positive Signals
- Livi’s Health Hub lists Mothercore as its online pelvic-floor physiotherapy partner.
- Selected for the 10-week DigitalHealth.London Launchpad programme for early-stage health companies.
- Completed Hive Founders’ eight-week Investment Readiness programme and pitched at Cohort XIII Demo Day.
- Partnered with Amaefamily in August 2026 to expand access to postpartum pelvic floor physiotherapy.
Team
Ksenia Fortin-Brazeau
Founder
- Led social strategy and later search strategy for Nestlé UK & Ireland, overseeing media strategy.
- Headed the integrated consumer experience team at Danone Healthcare, adding senior healthcare marketing and commercial experience.
- Angel investor and marketing adviser to Air Aware Labs, a UK air-quality health technology company.
Product
Mothercore delivers one-to-one pelvic floor physiotherapy by video to women in the UK. Patients book without a referral, receive an assessment from an HCPC-registered specialist, and get a personalised plan covering exercises, pressure management and activity guidance. Clinicians recommend in-person care when needed.
Direct access without a referral
A 50-minute initial consultation costs £85 and follow-ups £65. Sessions can be booked online without GP referral and cover history-taking, video-based movement and breathing assessment, and a personalised treatment plan.
Specialist care from regulated clinicians
All listed Mothercore physiotherapists are female, HCPC-registered and CSP members, with postgraduate pelvic-health training and professional liability insurance.
Continuous care with progress and outcome tracking
Mothercore supports women across pregnancy, postpartum, menopause and beyond, tracking adherence, progress and outcomes over follow-up care rather than treating each consultation as a standalone session.
Market Overview
England and Wales recorded 585,396 live births in 2025. NHS England reports that one in three women experience urinary incontinence in the first year after birth, with up to three quarters still affected over the following 12 years. Pelvic floor symptoms also occur around menopause, while RCOG polling found 69% of women had never discussed pelvic floor health with NHS staff.
England’s gynaecology waiting list reached 575,870 in June 2026, with 61% of patients seen within 18 weeks. RCOG says pelvic-health physiotherapy capacity cannot meet demand, while stress urinary incontinence has been estimated to cost the NHS £177 million annually. Mothercore targets this gap through self-pay, employer benefits and partners.
Share of 2,000 UK women reporting urinary incontinence in an RCOG-commissioned 2022 survey.
NHS England reports one in three women experience urinary incontinence in the first year after childbirth.
Women waiting for gynaecology care in England in the RCOG’s June 2026 data update.
Previous estimates put the annual NHS cost of stress urinary incontinence at £177 million.
Comparable Outcomes
Hinge Health
Hinge Health built software-guided musculoskeletal care for acute injuries, chronic pain and post-surgical recovery. Patients exercise at home with support from a clinical team. Hinge Health’s 2025 IPO priced 13.7M shares at $32, an offering of about $437M including secondary shares. It reported $213M in Q2 2026 revenue, up 53% year over year.
Progyny
Progyny built a fertility and family-building benefits platform sold to self-insured employers, combining benefit design with a specialist provider network and pharmacy services. Progyny went public in October 2019 at $13 a share. At the offer price, the company had a fully diluted market value of about $1.3 billion.
Interested in More Startups Like Mothercore?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.